What happened Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence. The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences (NASDAQ: GILD). ^SPX data by YCharts Gilead Sciences announced on March 2 that it had reached terms to acquire Forty Seven in a $4.9 billion deal that valued the immuno-oncology company at $95.50 per share. Forty Seven's share price jumped following the news to a level close to the buyout bid, and stayed relatively stable throughout the rest of the month while the broader market experienced downward pressure stemming from the COVID-19 pandemic. Image source: Getty Images. So what Both companies' boards of directors unanimously approved the deal to buy Forty Seven, with the purchase set to be carried out by Gilead's Toro Merger Sub subsidiary. A tender offer was issued on March 10 by Gilead and has since been completed. Gilead Sciences stock climbed roughly 7.8% in March, largely due to investors' hopes that its antiviral drug remdesivir (which was previously tested as a potential treatment for Ebola) could be effective against COVID-19, but also due to momentum from the Forty Seven acquisition. Now what Gilead and Forty Seven published press releases on April 7 announcing that the merger had been completed and that the smaller biotech company's stock had been converted at the agreed-upon price of $95.50 per share. The deal was Gilead's second major acquisition push into the immuno-oncology space, the first having been its 2017 purchase of Kite Pharma for $11.9 billion. 10 stocks we like better than Gilead SciencesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.Source